Home › Pharmacology › Principles of Pharmacotherapy for Parkinsonism

Principles of Pharmacotherapy for Parkinsonism

For medical students2 min readUpdated 2026-10-10

Pharmacotherapy for parkinsonism aims to compensate for dopamine deficiency in the central nervous system. The main treatment objective is to deliver the active substance directly into the brain by overcoming the body's physiological barriers.

Base DrugLevodopa (dopamine precursor)

Site of ActionCentral Nervous System (CNS)

BarrierBlood-Brain Barrier (BBB)

Drug ProtectionPeripheral decarboxylase inhibitors

Classification of Antiparkinsonian Agents

Several drug classes are used to correct motor impairments in parkinsonism, each with a distinct site of action in the nervous system.

The modern classification includes the following main groups:

Dopamine receptor agonists. A representative of this group is bromocriptine.
Central anticholinergics. These include trihexyphenidyl.
NMDA glutamate receptor blockers. The primary drug is amantadine.
Levodopa preparations. Levodopa itself serves as the core therapeutic agent.
Peripheral decarboxylase inhibitors. These include drugs such as carbidopa and benserazide. They are used exclusively as an auxiliary component to protect the primary active substance.

Mechanism of Action of Levodopa

The pharmacological effect of levodopa is based on its ability to stimulate dopaminergic transmission in brain structures.

Levodopa itself is a biochemical precursor of dopamine. To exert a therapeutic effect, the drug molecule must physically cross from the bloodstream into brain tissue. The main obstacle along this pathway is the blood-brain barrier (BBB), which isolates the central nervous system. Upon entering the CNS, the precursor is converted into the active neurotransmitter, replenishing its deficit.

Principles of Combination Therapy

Using pure levodopa presents a major pharmacokinetic challenge. The body contains an enzyme called aromatic L-amino acid decarboxylase. If a patient takes the drug unprotected, this enzyme actively metabolizes levodopa into dopamine in peripheral tissues (before the drug reaches the brain).

Peripherally formed dopamine is unable to cross the blood-brain barrier.

To solve this problem, combination therapy is used, pairing levodopa with carbidopa (or benserazide).

Goal and Result of the Combination:

Carbidopa reliably blocks the decarboxylase enzyme strictly in peripheral tissues.
Premature peripheral metabolism of levodopa into dopamine is prevented.
As a result, a significantly larger amount of unchanged drug successfully crosses the BBB directly into the central nervous system.

Mnemonic

To remember the essence of the combination, imagine: Levodopa is the "valuable cargo" heading to the brain, and Carbidopa is the "bodyguard" who distracts peripheral enzymes, allowing the cargo to safely cross the blood-brain barrier.

Frequently asked questions

What is the complete mechanism of the antiparkinsonian action of amantadine?

Amantadine has a mixed mechanism of action, affecting both dopamine and glutamate neurotransmitter systems.

Dopaminergic mechanism — enhances dopamine release from intact presynaptic terminals and impairs its neuronal reuptake.
Antiglutamatergic mechanism — blocks NMDA receptors on cholinergic neurons of the basal ganglia, preventing the stimulating action of glutamate and suppressing cholinergic transmission in the neostriatum.
Anticholinergic mechanism — possesses some intrinsic anticholinergic activity.

What side effects are characteristic of long-term therapy with levodopa preparations?

Levodopa therapy can lead to side effects across various organ systems.

Psychoneurological disorders — psychoses, hallucinations, anxiety, depression, insomnia, somnolence, and coordination disturbances.
Cardiovascular disorders — tachycardia and various cardiac arrhythmias associated with peripheral conversion of levodopa to dopamine and stimulation of myocardial β-adrenoceptors.
Gastrointestinal disorders — dyspeptic symptoms, specifically vomiting due to stimulation of the emetic center trigger zone.

Which drugs, besides bromocriptine, belong to the dopamine receptor agonist group?

In addition to bromocriptine, the dopamine receptor agonist group includes the following drugs:

Pergolide — a non-selective agonist derived from ergot alkaloids.
Pramipexole — a non-selective agonist stimulating D2 and D3-type receptors.
Ropinirole — a drug also used in extended-release formulations.
Piribedil — a drug that additionally enhances noradrenergic transmission.

How does the mechanism of action of levodopa fundamentally differ from that of bromocriptine?

The fundamental difference is that levodopa is a neurotransmitter precursor, whereas bromocriptine is a direct receptor agonist.

Characteristic	Levodopa (Levodopa)	Bromocriptine (Bromocriptine)
Mechanism of Action	Dopamine precursor requiring metabolic conversion	Direct dopamine receptor agonist
Site of Action	Converted to dopamine by DOPA decarboxylase	Direct stimulation of receptors in the neostriatum

What is the role of COMT inhibitors (entacapone) in the combination therapy of parkinsonism?

COMT inhibitors block the catabolic pathways of levodopa and dopamine. Entacapone is used in combination with levodopa and carbidopa. This combination is utilized to manage motor fluctuations.

What is the main mechanism of action of levodopa?

Levodopa is a dopamine precursor. Its primary effect is due to the stimulation of dopaminergic transmission in the central nervous system.

What role does carbidopa play in treatment?

Carbidopa acts as an auxiliary component. It blocks the aromatic L-amino acid decarboxylase enzyme in the periphery, preventing levodopa from breaking down before reaching the brain.

What barrier must levodopa cross to exert its effect?

The drug must penetrate the blood-brain barrier (BBB) to enter the central nervous system.

Go deeper

Mechanism of action of central anticholinergics (trihexyphenidyl)
Pharmacodynamics of dopamine receptor agonists (bromocriptine)
NMDA glutamate receptor blockade: effects of amantadine
Comparative profile of peripheral decarboxylase inhibitors (carbidopa and benserazide)